Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients – Long term data on toxicity and biochemical control
Schiller K, Geier M, Duma MN, Nieder C, Molls M, Combs SE, Geinitz H (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 24
Pages Range: 315-321
Journal Issue: 4
DOI: 10.1016/j.rpor.2019.05.004
Abstract
Aim: To report long-term data regarding biochemical control and late toxicity of simultaneous integrated boost intensity modulated radiotherapy (SIB-IMRT)with tomotherapy in patients with localized prostate cancer. Background: Dose escalation improves cancer control after curative intended radiation therapy (RT)to patients with localized prostate cancer, without increasing toxicity, if IMRT is used. Materials and methods: In this retrospective analysis, we evaluated long-term toxicity and biochemical control of the first 40 patients with intermediate risk prostate cancer receiving SIB-IMRT. Primary target volume (PTV)1 including the prostate and proximal third of the seminal vesicles with safety margins was treated with 70 Gy in 35 fractions. PTV 2 containing the prostate with smaller safety margins was treated as SIB to a total dose of 76 Gy with 2.17 Gy per fraction. Toxicity was evaluated using an adapted CTCAE-Score (Version 3). Results: Median follow-up of living patients was 66 (20–78)months. No late genitourinary toxicity higher than grade 2 has been reported. Grade 2 genitourinary toxicity rates decreased from 58% at the end of the treatment to 10% at 60 months. Late gastrointestinal (GI)toxicity was also moderate, though the prescribed PTV Dose of 76 Gy was accepted at the anterior rectal wall. 74% of patients reported any GI toxicity during follow up and no toxicity rates higher than grade 2 were observed. Grade 2 side effects were reported by 13% of the patients at 60 months. 5-year freedom from biochemical failure was 95% at our last follow up. Conclusion: SIB-IMRT using daily MV-CT guidance showed excellent long-term biochemical control and low toxicity rates.
Involved external institutions
Technische Universität München (TUM)
Germany (DE)
Nordland Hospital / Nordlandssykehuset
Norway (NO)
Germany (DE)
Nordland Hospital / Nordlandssykehuset
Norway (NO)
How to cite
APA:
Schiller, K., Geier, M., Duma, M.N., Nieder, C., Molls, M., Combs, S.E., & Geinitz, H. (2019). Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients – Long term data on toxicity and biochemical control. Reports of Practical Oncology and Radiotherapy, 24(4), 315-321. https://doi.org/10.1016/j.rpor.2019.05.004
MLA:
Schiller, Kilian, et al. "Definitive, intensity modulated tomotherapy with a simultaneous integrated boost for prostate cancer patients – Long term data on toxicity and biochemical control." Reports of Practical Oncology and Radiotherapy 24.4 (2019): 315-321.
BibTeX: Download